Navigation Links
Kendle to Share Insights at Drug Information Association 45th Annual Meeting
Date:6/17/2009

CINCINNATI, June 17 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced that several of its executives will present on important industry issues at the Drug Information Association (DIA) 45th Annual Meeting June 21-25, 2009, in San Diego, Calif. Kendle experts will address key topics in clinical development, including regulatory issues in portfolio management, pregnancy registries and risk management, and patient recruitment and retention for pregnancy registries.

Kendle Speakers

    Wednesday, June 24, 3:30-5 p.m., Room 14B
    Managing Development Portfolios in a Safety-Heightened Environment
    William K. Sietsema, PhD
    Vice President, U.S. Regulatory Consulting and Submissions

    Thursday, June 25, 8:30-10 a.m.
    Pregnancy Registries: Perspectives on a Unique Risk Management Tool
    Deborah Covington, DrPH, MS, Senior Director, Late Phase
    Laura F. McKain, MD, Medical Director, Registries and Epidemiology, Late
     Phase

    Poster Presentation
    Pregnancy Exposure Registries: Enhancing Recruitment and Retention
    Deborah Covington, DrPH, MS
    Senior Director, Late Phase

Kendle at Booth #439

Kendle experts will be available for on-site meetings and to discuss the Company's model for consistent quality execution of Phase I-IV clinical development programs and best practices in the development of strategic customer relationships.

In addition to Phase I-IV clinical development capabilities, the Kendle display also will highlight the Company's continued and recent success in delivering consistent quality and building effective site relationships as validated by independent third-party quantitative research. Kendle recently was named the highest-rated top-five CRO in the 2009 CenterWatch Survey of U.S. Investigative Sites. The Company is the only CRO to have been ranked consistently among the top two providers in the 2009, 2008 and 2007 CenterWatch surveys of U.S. and European investigative sites. In addition, according to the "2009 CRO Quality Benchmarking Report" published by Industry Standard Research (ISR), "Kendle delivers the most consistent quality services" as measured by the "Service Variability Index" (SVI), a measurement of consistency, which researchers at ISR identified as the most significant indicator of quality. Kendle's industry-best score was 12.2 (lower score = less variability, and closer to ideal distribution), while the industry average was 25.1. Kendle rated highest among CROs in the areas of CRA Quality, Consistent Quality Delivery, Meeting Project Timelines and Efficient Site Start-up.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the fastest-growing global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 500, Cincinnati, OH 45202 or from the Company's Web site at www.kendle.com.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080923/CLTU095LOGO)


'/>"/>
SOURCE Kendle International Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Kendle to Present at Upcoming Jefferies and Wachovia Securities Conferences
2. Kendle Announces First Quarter 2009 Earnings Conference Call and Webcast
3. Kendle Expands Asia/Pacific Operations with Opening of Additional Office in India
4. Kendle Revises Full Year 2008 Guidance
5. Kendle to Present at 27th Annual J.P. Morgan Healthcare Conference
6. Kendle Delivers Record Sales, Net Service Revenues and Earnings Per Share for Second Quarter 2008
7. Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008
8. Kendle Promotes Simon S. Higginbotham to President; Appoints Alan J. Boyce as Chief Marketing Officer
9. Kendle Delivers Strong Growth in Revenues, New Business Authorizations and Operating Margin for Full-Year 2007; Announces Guidance for 2008
10. Kendle Invites You to Attend Its Fourth Quarter and Year End 2007 Earnings Conference Call and Webcast
11. Kendle Appoints Industry Veteran to Lead Asia/Pacific Expansion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing skills ... patients and their families pay tribute to a genetic counselor by nominating him or ... Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome magazine ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
Breaking Medicine Technology: